UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Recruiting · NCT06590961 · Registry updated 2025-11-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 | 2025-11-19 | NCT06590961 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ubix Therapeutics, Inc. | 1 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AidPort | Grodzisk Wielkopolski | Poland | 1 |
| Asan Medical Center | Seoul | South Korea | 22 |
| Gabrail Cancer Center | Canton | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| MICS Centrum Medyczne Toruń | Torun | Poland | 1 |
| Pratia, MTZ Clinical Research | Warsaw | Poland | 1 |
| Pratia, Oncology Katowice | Katowice | Poland | 1 |
| Samsung Medical Center | Seoul | South Korea | 42 |
| The Catholic University of Korea, Seoul St. Mary's Hospital | Seoul | South Korea | 2 |
| The Catholic University of Korea, Yeouido St. Mary's Hospital | Seoul | South Korea | 2 |
| University of Michigan | Ann Arbor | United States | 538 |